Fig. 3

Targeted therapies for capillary venous malformations in PIK3CA^Tie2-CreER mice. a Kaplan–Meier survival curves of PIK3CA^WT and PIK3CA^Tie2-CreER mice treated with either vehicle, rapamycin, miransertib or alpelisib (n = 12 per group). b Coronal whole-body T2-weighted magnetic resonance images (MRI) of PIK3CA^WT and PIK3CA^Tie2-CreER mice 6 weeks after Cre recombination treated with either vehicle, rapamycin, miransertib or alpelisib. Volumetric quantification of the vascular malformations (n = 3-4 mice per group). c Complete blood count in PIK3CA^WT and PIK3CA^Tie2-CreER mice treated with either vehicle, rapamycin, miransertib or alpelisib (n = 3–5 mice per group). d Representative hematoxylin and eosin (H&E) staining of the skin of PIK3CA^WT and PIK3CA^Tie2-CreER mice treated with either vehicle, rapamycin, miransertib or alpelisib. Scale bar: 10 μm. e Representative P-AKT^Thr308 and P-S6RP immunostaining in the skin of PIK3CA^WTand PIK3CA^Tie2-CreER mice treated with either vehicle, rapamycin, miransertib or alpelisib. Scale bar: 10 μm. f Western blot and quantification of P-AKT^Ser473 and P-S6RP of the skin of PIK3CA^WTand PIK3CA^Tie2-CreER mice treated with either vehicle, rapamycin, miransertib or alpelisib (n = 3–4 per group). g Representative immunofluorescence staining of KI67 in the skin of PIK3CA^WTand PIK3CA^Tie2-CreER mice treated with either vehicle, rapamycin, miransertib or alpelisib. Scale bar: 10 μm. h Proliferation index quantification (n = 3–4 mice per group)